Kelvin Moses, MD, PhD, anticipates that AUA 2024 will showcase advancements in key areas of metastatic prostate cancer, including updated guidance on molecular imaging from new joint AUA/ASTRO/SUO guidelines on Salvage Therapy for Prostate Cancer, particularly PSMA PET imaging. Additionally, Dr Moses expects to hear new data on immunotherapy, especially PARP inhibitors like olaparib and rucaparib for BRCA1/2 disease, as well as immunotherapies like talazoparib for homologous recombination repair deficient prostate cancer.
The conference will also highlight updates on trials such as the VISION study, focusing on lutetium-based therapies in combination with anti-androgens. With the goal of improving overall and disease-specific survival, Dr Moses concludes that updates on guidelines, advanced imaging, theranostics, and immunotherapy will have the greatest impact.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: AUA 2024: Awaiting New Data in the Treatment of Metastatic Prostate Cancer - Medscape - Apr 26, 2024.
Comments